以雷贝拉唑为基础的不同疗程三联疗法治疗H.pylori感染疗效Meta分析

发布时间：2018-01-14 10:23

  本文关键词：以雷贝拉唑为基础的不同疗程三联疗法治疗H.pylori感染疗效Meta分析　出处：《重庆医科大学》2016年硕士论文　论文类型：学位论文

  更多相关文章： 雷贝拉唑 三联疗法 H.pylori 疗程 meta分析

【摘要】：目的:对以雷贝拉唑为基础的三联疗法根治H.pylori感染7d、10d、14d疗效进行meta分析,以客观评价其疗效。方法:计算机检索维普数据库、万方数据库、中国知网数据库(CNKI)、PubMed数据库,查找以雷贝拉唑为基础的不同疗程三联疗法治疗H.pylori感染的相关文献,运用Review Manager5.2软件对文献数据进行分析。结果:以雷贝拉唑为基础的三联疗法在H.pylori根除率方面,10d和14d疗程效果优于7d疗程,差异具有统计学意义(7d vs 10d:OR0.72,95%CI 0.53~0.96,P=0.03;7d vs 14d:OR 0.49,95%CI0.31~0.79,P=0.003),但10d和14d疗程差异无统计学意义(OR 0.79,95%CI 0.47~1.34,P=0.39);在不良反应发生率方面,7d、10d、14d三个疗程分别两两组间对比,差异均无统计学意义(7d vs 10d:OR1.05,95%CI 0.75~1.47,P=0.78;7d vs 14d:OR 0.80,95%CI0.32~2.00,P=0.63;10d vs 14d:OR 0.82,95%CI 0.45~1.50,P=0.53);在临床症状缓解率方面,上述各组间对比亦无统计学证据支持何种疗程更加有效(7d vs 10d:OR 0.79,95%CI 0.31~2.04,P=0.63;7d vs 14d:OR 0.72,,95%CI 0.26~2.00,P=0.53;10d vs 14d:OR 0.92,95%CI0.32~2.63,P=0.87)。结论:在以雷贝拉唑为基础的三联疗法治疗H.pylori感染时,10d与14d疗程效果优于7d疗程,但10d与14d疗程间无统计学差异。因此,结合患者经济负担及依从性考虑,建议用药10d则可达到治疗目的,但这仍需更多大样本临床随机对照研究进一步证实。
[Abstract]:Objective: to analyze the efficacy of triple therapy based on rabeprazole in the treatment of H.pylori infection for 10 days and 14 days. Methods: the database of Weip, Wanfang and CNKI / PubMed were searched by computer. To find the literature on the treatment of H.pylori infection with different courses of triple therapy based on rabeprazole. Review Manager5.2 software was used to analyze the literature data. Results: triple therapy based on rabeprazole was used in H. pylori eradication rate. The therapeutic effect of 10d and 14d was better than that of 7d. The difference was statistically significant (7d vs 10d OR0.72N). 7 days vs 14 d OR: 0.49% 95% CI 0.31 ~ 0.79%, but there was no significant difference between 10 days and 14 days course of treatment (OR 0.79). 95 CI 0.47 ~ 1.34 ~ 0.39%; There were no significant differences in the incidence of adverse reactions between the two groups for 7 days or 10 days or 14 days, and there was no significant difference between the two groups (7 days vs 10 d OR 1.05). 95 CI 0.75 ~ 1.47 ~ 0.78; 7 days vs 14 days OR 0.80 / 95 / CI 0.32 / 2.00 / 0.63; 10 days vs 14 days OR 0.8295 / CI 0.45 1.50 / 0.53; In the clinical symptom remission rate, there is no statistical evidence between the above groups to support which course of treatment is more effective 7 days vs 10 d: OR 0.79 95 CI 0.31 卤2.04. P0. 63; 7 days vs 14 days OR 0.72 / 95 CI 0.26 / 2.00 / 0.53; 10d vs 14dOR 0.9295 CI 0.32 / 2.63. Conclusion: in the treatment of H.pylori infection based on rabeprazole, the therapeutic effect of 10 days and 14 days is better than that of 7 days. However, there was no statistical difference between 10 days and 14 days of treatment. Therefore, considering the financial burden and compliance of the patients, it was suggested that 10 days of medication could achieve the purpose of treatment. But this still needs to be further confirmed by a large sample of clinical randomized controlled studies.
【学位授予单位】：重庆医科大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R573

【参考文献】

相关期刊论文 前8条

1 Fatih Ermis;Elif Senocak Tasci;;Current Helicobacter pylori treatment in 2014[J];World Journal of Methodology;2015年02期

2 Florian Anderl;Markus Gerhard;;Helicobacter pylori vaccination:Is there a path to protection?[J];World Journal of Gastroenterology;2014年34期

3 Jun Heo;Seong Woo Jeon;;Optimal treatment strategy for Helicobacter pylori:Era of antibiotic resistance[J];World Journal of Gastroenterology;2014年19期

4 Chang Seok Bang;Gwang Ho Baik;;Attempts to enhance the eradication rate of helicobacter pylori infection[J];World Journal of Gastroenterology;2014年18期

5 Jyh-Chin Yang;Chien-Wei Lu;Chun-Jung Lin;;Treatment of Helicobacter pylori infection:Current status and future concepts[J];World Journal of Gastroenterology;2014年18期

6 Han-Yi Song;Yan Li;;Can eradication rate of gastric Helicobacter pylori be improved by killing oral Helicobacter pylori ?[J];World Journal of Gastroenterology;2013年39期

7 Hyuk Soon Choi;Hoon Jai Chun;Sang Hoon Park;Bora Keum;Yeon Seok Seo;Yong Sik Kim;Yoon-Tae Jeen;Soon Ho Um;Hong Sik Lee;Chang Duck Kim;Ho Sang Ryu;;Comparison of sequential and 7-,10-,14-d triple therapy for Helicobacter pylori infection[J];World Journal of Gastroenterology;2012年19期

8 Alexander C Ford;Peter Malfertheiner;Monique Giguère;José Santana;Mostafizur Khan;Paul Moayyedi;;Adverse events with bismuth salts for Helicobacter pylori eradication:Systematic review and meta-analysis[J];World Journal of Gastroenterology;2008年48期

，

本文编号：1423171